ArriVent BioPharma, Inc. Common Stock Total Assets
ArriVent BioPharma, Inc. Common Stock total assets. Based on the latest financial reports, ArriVent BioPharma, Inc. Common Stock (AVBP) holds total assets worth $394.72 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see market value of ArriVent BioPharma, Inc. Common Stock for the company's overall valuation and market capitalisation.
Total Assets of ArriVent BioPharma, Inc. Common Stock (2021–2025)
Total assets of ArriVent BioPharma, Inc. Common Stock from 2021 to 2025. This chart illustrates how ArriVent BioPharma, Inc. Common Stock's total assets have evolved over time, based on quarterly financial data. See current stock price of ArriVent BioPharma, Inc. Common Stock for real-time trading data and today's change.
ArriVent BioPharma, Inc. Common Stock - Asset Composition Analysis
ArriVent BioPharma, Inc. Common Stock Total Assets Breakdown (September 2025)
ArriVent BioPharma, Inc. Common Stock total assets breakdown as of September 2025. ArriVent BioPharma, Inc. Common Stock's total assets of $394.72 Million consist of 99.9% current assets and 0.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 13.7% |
| Accounts Receivable | $60.00K | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how ArriVent BioPharma, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore how liquid is ArriVent BioPharma, Inc. Common Stock's working capital to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ArriVent BioPharma, Inc. Common Stock's current assets represent 99.9% of total assets in 2025, an increase from 99.8% in 2021.
- Cash Position: Cash and equivalents constituted 13.7% of total assets in 2025, down from 86.6% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is accounts receivable at 0.0% of total assets.
ArriVent BioPharma, Inc. Common Stock Competitors by Total Assets
Key competitors of ArriVent BioPharma, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
ArriVent BioPharma, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 14.16 | 12.74 | 21.84 |
| Quick Ratio | 14.16 | 12.74 | 21.84 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $366.33 Million | $230.51 Million | $174.26 Million |
ArriVent BioPharma, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between ArriVent BioPharma, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.07 |
| Latest Market Cap to Assets Ratio | 1.93 |
| Asset Growth Rate (YoY) | 21.2% |
| Total Assets | $333.17 Million |
| Market Capitalization | $641.99 Million USD |
Valuation Analysis
Above Book Valuation: The market values ArriVent BioPharma, Inc. Common Stock's assets above their book value (1.93x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: ArriVent BioPharma, Inc. Common Stock's assets grew by 21.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for ArriVent BioPharma, Inc. Common Stock (2021–2025)
The table below shows the annual total assets of ArriVent BioPharma, Inc. Common Stock from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-09-30 | $333.17 Million | +21.18% |
| 2024-09-30 | $274.94 Million | +68.57% |
| 2023-09-30 | $163.10 Million | -10.79% |
| 2022-09-30 | $182.83 Million | +324.81% |
| 2021-09-30 | $43.04 Million | -- |
About ArriVent BioPharma, Inc. Common Stock
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutati… Read more